Trials / Withdrawn
WithdrawnNCT00820742
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.
Detailed description
Open-label, non-comparative, non-interventional study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Macugen | Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2009-01-12
- Last updated
- 2015-03-05
Source: ClinicalTrials.gov record NCT00820742. Inclusion in this directory is not an endorsement.